Pulmatrix (PULM) Total Current Liabilities (2014 - 2026)
Pulmatrix (PULM) posted Total Current Liabilities of $905000.0 for Q1 2026, up 175.08% sequentially from $329000.0 in Q4 2025, and little changed YoY from $903000.0 in Q1 2025.
Pulmatrix (PULM) Total Current Liabilities (2014 - 2026) Analysis & Trends
Pulmatrix has reported Total Current Liabilities for 13 years, with the latest figure at $905000.0 in Q1 2026.
- Quarterly Total Current Liabilities changed 0.22% year-over-year to $905000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $905000.0 (changed 0.22% YoY) and the FY2025 annual result came in at $329000.0, down 64.59% from the prior year.
- Total Current Liabilities advanced to $905000.0 in Q1 2026 per PULM's latest filing, from $329000.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $6.3 million in Q3 2022 and troughed at $249000.0 in Q3 2025.
- A 5-year average of $2.9 million and a median of $3.1 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities grew 23.23% in 2022, then plunged 86.68% in 2024.
- Over 5 years, Total Current Liabilities stood at $5.0 million in 2022, then slipped by 22.16% to $3.9 million in 2023, then plunged by 76.23% to $929000.0 in 2024, then tumbled by 64.59% to $329000.0 in 2025, then surged by 175.08% to $905000.0 in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $905000.0, $329000.0, and $249000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Pulmatrix | 5.55 Mn | 5.55 Mn | - | 689,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 689,000.00 |
| Mar 31, 2026 | 905,000.00 |
| Dec 31, 2025 | 329,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 548,000.00 |
| Mar 31, 2025 | 903,000.00 |
| Dec 31, 2024 | 929,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 3.60 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 5.02 Mn |
| Sep 30, 2022 | 6.32 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 5.38 Mn |
| Dec 31, 2021 | 4.44 Mn |
| Sep 30, 2021 | 5.13 Mn |